Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 5 completed trials

    Completion Rate
    100%(5/5)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 3
    2
    40%
    Phase 1
    2
    40%
    Phase 2
    1
    20%

    Phase Distribution

    2

    Early Stage

    1

    Mid Stage

    2

    Late Stage

    Phase Distribution5 total trials
    Phase 1Safety & dosage
    2(40.0%)
    Phase 2Efficacy & side effects
    1(20.0%)
    Phase 3Large-scale testing
    2(40.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    5 of 5 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    5

    all time

    Status Distribution
    Completed(5)

    Detailed Status

    Completed5

    Development Timeline

    Analytics

    Development Status

    Total Trials
    5
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 12 (40.0%)
    Phase 21 (20.0%)
    Phase 32 (40.0%)

    Trials by Status

    completed5100%

    Recent Activity

    0 active trials
    Showing 5 of 5
    completedphase_1

    Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

    NCT00198458
    completedphase_2

    Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment

    NCT00198471
    completedphase_3

    Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

    NCT00198510
    completedphase_1

    Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

    NCT00198419
    completedphase_3

    Evaluation of Vitrase as a Spreading Agent

    NCT00198484

    Clinical Trials (5)

    Showing 5 of 5 trials
    NCT00198458Phase 1

    Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

    Completed
    NCT00198471Phase 2

    Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment

    Completed
    NCT00198510Phase 3

    Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

    Completed
    NCT00198419Phase 1

    Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

    Completed
    NCT00198484Phase 3

    Evaluation of Vitrase as a Spreading Agent

    Completed

    All 5 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    5